Holen Sie sich die Stockscreener-App
21.54
2.43%
0.51
Vorhandelsmarkt:
21.97
0.43
+2.00%
Schlusskurs vom Vortag:
$21.03
Offen:
$21.41
24-Stunden-Volumen:
1.94M
Relative Volume:
0.94
Marktkapitalisierung:
$2.17B
Einnahmen:
$352.57M
Nettoeinkommen (Verlust:
$-143.01M
KGV:
-11.90
EPS:
-1.81
Netto-Cashflow:
$-153.40M
1W Leistung:
+10.01%
1M Leistung:
+28.52%
6M Leistung:
-18.38%
1J Leistung:
-20.37%
1-Tages-Spanne:
$20.86
$21.75
1-Wochen-Bereich:
$19.66
$22.80
52-Wochen-Spanne:
$13.53
$35.25
Beam Therapeutics Inc Stock (BEAM) Company Profile
Firmenname
Beam Therapeutics Inc
Sektor
Branche
Telefon
857-327-8775
Adresse
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Vergleichen Sie BEAM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
21.54 | 1.97B | 352.57M | -143.01M | -153.40M | -1.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-28 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-03-10 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2025-01-29 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-06 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-07-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-01-29 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-12-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-12-08 | Herabstufung | Jefferies | Buy → Hold |
| 2023-10-20 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-20 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2023-03-21 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-02-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-12-20 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-12-13 | Eingeleitet | Citigroup | Buy |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2022-04-28 | Eingeleitet | Credit Suisse | Neutral |
| 2022-01-05 | Eingeleitet | Guggenheim | Buy |
| 2021-10-19 | Eingeleitet | SVB Leerink | Outperform |
| 2021-09-24 | Fortgesetzt | Stifel | Buy |
| 2021-09-10 | Eingeleitet | BofA Securities | Buy |
| 2021-05-11 | Eingeleitet | Redburn | Buy |
| 2021-05-04 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2021-03-01 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2021-02-16 | Eingeleitet | Wells Fargo | Overweight |
| 2021-01-29 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-01-06 | Eingeleitet | Stifel | Hold |
| 2020-08-05 | Eingeleitet | William Blair | Outperform |
| 2020-03-02 | Eingeleitet | Barclays | Overweight |
| 2020-03-02 | Eingeleitet | JP Morgan | Overweight |
| 2020-03-02 | Eingeleitet | Jefferies | Buy |
| 2020-03-02 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Beam Therapeutics Inc Aktie (BEAM) Neueste Nachrichten
Beam Therapeutics Inc. Stock Analysis and ForecastExplosive returns - jammulinksnews.com
What drives Beam Therapeutics Inc. stock priceDynamic investment opportunities - jammulinksnews.com
What analysts say about Beam Therapeutics Inc. stockFree High-Return Strategy Alerts - jammulinksnews.com
Is Beam Therapeutics Inc. a good long term investmentRobust financial gains - jammulinksnews.com
Sickle Cell Disease Market Set to Grow Substantially Through 2034, DelveInsight Projects | Sanofi, CSL Behring, ITB-Med LLC, Novo Nordisk A/S, Fortrea, Inc., Novartis, Afimmune, Pfizer, ADDMEDICA SASA - The Globe and Mail
Beam Therapeutics (BEAM) Announces Acquisition of an Early-Stage Life Sciences Company - MSN
12 Oversold NASDAQ Stocks to Buy Now - Insider Monkey
(BEAM) Trading Report - news.stocktradersdaily.com
Beam Therapeutics (BEAM) Surges 5.7%: Is This an Indication of Further Gains? - MSN
H.C. Wainwright Reiterates a Buy Rating on Beam Therapeutics (BEAM) With an $80 PT - MSN
Cathie Wood’s ARK ETF bolsters Beam stock, sheds Roblox - Investing.com
Beam Therapeutics: A Base Editing Breakthrough With Catalysts to Ignite Value - AInvest
Beam Therapeutics’ BEAM-101 Shows Promising Results in Sickle Cell Disease Trial - MSN
Beam Therapeutics Acquires Early-Stage Life Sciences Firm - The Globe and Mail
H.C. Wainwright reiterates Buy rating on Beam Therapeutics stock at $80 target - Investing.com
Beam Therapeutics: A Contrarian Opportunity in Gene Editing Amid Russell Reconstitution - AInvest
Top 10 CRISPR Stocks to Buy Now - Insider Monkey
Beam Therapeutics Inc.(NasdaqGS: BEAM) dropped from Russell 3000 Value Index - MarketScreener
3 Promising Genomics Stocks to Keep an Eye On in 2025 - The Globe and Mail
BEAM-101 shows sustained benefits as treatment for sickle cell - Sickle Cell Disease News
Beam Therapeutics: Progress Of BEAM-101 Presses Forward With H2 2025 Data Releases - Seeking Alpha
Can Casgevy Deliver a Turnaround for CRISPR Therapeutics? - Yahoo Finance
Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst - Benzinga
Gene-Editing Stocks Gain on LLY-VERV Deal Announcement - Yahoo Finance
Editas Medicine Is Great. Here's Why You Shouldn't Buy It. - The Motley Fool
BEAM Therapeutics’ SWOT analysis: base editing pioneer’s stock faces pivotal year - Investing.com
H.C. Wainwright reiterates buy rating on Beam Therapeutics stock By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates buy rating on Beam Therapeutics stock - Investing.com
Cathie Wood’s ARK ETFs adjust holdings, buying GitLab and Beam Therapeutics stock - Investing.com Nigeria
Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clini - GuruFocus
Beam Therapeutics Announces New Data from BEACON Phase 1/2 - GlobeNewswire
Beam Therapeutics (BEAM) Reports Strong Results for Sickle Cell Therapy - GuruFocus
Beam reports positive results from sickle cell disease treatment - Seeking Alpha
Beam Therapeutics reports positive data from sickle cell therapy trial - Investing.com
Finanzdaten der Beam Therapeutics Inc-Aktie (BEAM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):